Population pharmacokinetic model for docetaxel in patients with varying degrees of liver function: Incorporating cytochrome P450 3A activity measurements

Clinical Pharmacology and Therapeutics

Volumn 84, Issue 1, 2008, Pages 111-118

  Hooker, A C ^a   Ten Tije, A J ^b   Carducci, M A ^c   Weber, J ^c   Garrett Mayer, E ^c   Gelderblom, H ^d   McGuire, W P ^e   Verweij, J ^b   Karlsson, M O ^a   Baker, S D ^c  

^a UPPSALA UNIVERSITY   (Sweden)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c JOHNS HOPKINS UNIVERSITY   (United States)

^d LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^e Franklin Square Hospital Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 3A; CYTOCHROME P450 3A4; DOCETAXEL; ERYTHROMYCIN;

ADULT; ADVANCED CANCER; AGED; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BREAST CANCER; BREATH ANALYSIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG CLEARANCE; DRUG SAFETY; ENZYME ACTIVITY; ENZYME ANALYSIS; ERYTHROMYCIN BREATH TEST; FEBRILE NEUTROPENIA; FEMALE; HEAD AND NECK CANCER; HUMAN; LIVER CLEARANCE; LIVER DYSFUNCTION; LIVER FUNCTION; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MELANOMA; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MULTIVARIATE ANALYSIS OF COVARIANCE; NEUTROPENIA; PRIORITY JOURNAL; PROSTATE CANCER; SIDE EFFECT; THROMBOCYTOPENIA;

ADULT; AGED; CYTOCHROME P-450 CYP3A; ENZYME ACTIVATION; FEMALE; HUMANS; LIVER; LIVER FUNCTION TESTS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; PROSPECTIVE STUDIES; RESEARCH DESIGN; TAXOIDS;

EID: 45549101956     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/sj.clpt.6100476     Document Type: Article

References (21)

1. Bruno, R. et al. Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer. J. Clin. Oncol. 16, 187-196 (1998).
2. Bruno, R., Vivier, N., Veyrat-Follet, C., Montay, G. & Rhodes, G.R. Population pharmacokinetics and pharmacokinetic-pharmacodynamic relationships for docetaxel. Invest. New Drugs 19, 163-169 (2001).
3. Bruno, R. et al. Alpha-1-acid glycoprotein as an independent predictor for treatment effects and a prognostic factor of survival in patients with non-small cell lung cancer treated with docetaxel. Clin. Cancer Res. 9, 1077-1082 (2003).
4. Shou, M., Martinet, M., Korzekwa, K.R., Krausz, K.W., Gonzalez, F.J. & Gelboin, H.V. Role of human cytochrome P450 3A4 and 3A5 in the metabolism of taxotere and its derivatives: enzyme specificity, interindividual distribution and metabolic contribution in human liver. Pharmacogenetics 8, 391-401 (1998).
5. Baker, S.D., Sparreboom, A. & Verweij, J. Clinical pharmacokinetics of docetaxel: recent developments. Clin. Pharmacokinet. 45, 235-252 (2006).
6. Yamamoto, N., Tamura, T., Kamiya, Y., Sekine, I., Kunitoh, H. & Saijo, N. Correlation between docetaxel clearance and estimated cytochrome P450 activity by urinary metabolite of exogenous cortisol. J. Clin. Oncol. 18, 2301-2308 (2000).
7. Goh, B.C. et al. Explaining interindividual variability of docetaxel pharmacokinetics and pharmacodynamics in Asians through phenotyping and genotyping strategies. J. Clin. Oncol. 20, 3683-3690 (2002).
8. Hirth, J., Watkins, P.B., Strawderman, M., Schott, A., Bruno, R. & Baker, L.H. The effect of an individual's cytochrome CYP3A4 activity on docetaxel clearance. Clin. Cancer Res. 6, 1255-1258 (2000).
9. Slaviero, K.A., Clarke, S.J., McLachlan, A.J., Blair, E.Y. & Rivory, L.P. Population pharmacokinetics of weekly docetaxel in patients with advanced cancer. Br. J. Clin. Pharmacol. 57, 44-53 (2004).
10. Puisset, F., Chatelut, E., Dalenc, F., Busi, F., Cresteil, T., Azema, J. et al. Dexamethasone as a probe for docetaxel clearance. Cancer Chemother. Pharmacol. 54, 265-272 (2004).
11. Fossella, F.V. et al. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group. J. Clin. Oncol. 18, 2354-2362 (2000).
12. Minami, H. et al. Comparison of pharmacokinetics and pharmacodynamics of docetaxel and Cisplatin in elderly and non-elderly patients: why is toxicity increased in elderly patients? J. Clin. Oncol. 22, 2901-2908 (2004).
13. ten Tije, A.J. et al. Prospective evaluation of the pharmacokinetics and toxicity profile of docetaxel in the elderly. J. Clin. Oncol. 23, 1070-1077 (2005).
14. Bruno, R., Vivler, N., Vergniol, J.C., De Phillips, S.L., Montay, G. & Sheiner, L.B. A population pharmacokinetic model for docetaxel (Taxotere): model building and validation. J. Pharmacokinet. Biopharm. 24, 153-172 (1996).
15. Baker, S.D. et al. A phase I and pharmacokinetic study of docetaxel in cancer patients with liver dysfunction due to malignancies. Proc. Am. Soc. Clin. Oncol. 17, 192a (1998).
16. Synold, T.W. et al. Prospective evaluation of docetaxel (D) pharmacokinetics (PK) and toxicity in patients with tumor-related hepatic dysfunction (HD). Proc. Am. Soc. Clin. Oncol. 18, 168a (1999).
17. Baker, S.D. et al. Factors affecting cytochrome P-450 3A activity in cancer patients. Clin. Cancer. Res. 10, 8341-8350 (2004).
18. Baker, S.D., Zhao, M., He, P., Carducci, M.A., Verweij, J. & Sparreboom, A. Simultaneous analysis of docetaxel and the formulation vehicle polysorbate 80 in human plasma by liquid chromatography/tandem mass spectrometry. Anal. Biochem. 324, 276-284 (2004).
19. Acharya, M.R., Baker, S.D., Verweij, J., Figg, W.D. & Sparreboom, A. Determination of fraction unbound docetaxel using micro-equilibrium dialysis. Anal. Biochem. 331, 192-194 (2004).
20. Jonsson, E.N. & Karlsson, M.O. Xpose - an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM. Comput. Methods Programs Biomed. 58, 51-64 (1999).
21. Derksen, S. & Keselman, J. Backward, forward and stepwise automated subset selection algorithms: frequency of obtaining authentic and noise variables. Br. J. Math. Stat. Psych. 45, 265-282 (1992).